文献速递心力衰竭与心肌病

沙库巴曲/缬沙坦治疗晚期射血分数降低心衰的随机试验

Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2022-01-01

该双盲随机试验纳入335例晚期射血分数降低心衰且近期NYHA IV级症状患者,比较沙库巴曲/缬沙坦与缬沙坦对24周NT-proBNP比值AUC的影响。结果显示两组NT-proBNP AUC变化比值0.95(95%CI 0.84-1.08;沙库巴曲/缬沙坦组非危及生命高钾血症发生率更高(17% vs 9%;

要点

  • 在晚期HFrEF且近期NYHA IV级患者中,沙库巴曲/缬沙坦未显著降低NT-proBNP水平。
  • 沙库巴曲/缬沙坦组非危及生命高钾血症发生率显著高于缬沙坦组(17% vs 9%)。
  • 沙库巴曲/缬沙坦未改善存活且院外无心衰事件的复合终点。

核心结论

  • 在慢性晚期射血分数降低心衰患者中,沙库巴曲/缬沙坦与缬沙坦相比在降低NT-proBNP水平方面无统计学显著差异。

研究设计与样本

  • 双盲随机临床试验,纳入335例晚期心衰患者,随机接受沙库巴曲/缬沙坦(目标剂量200 mg每日两次)或缬沙坦(目标剂量160 mg每日两次)加推荐治疗。
  • 试验于2017年3月2日开始,2020年3月23日因COVID-19风险提前终止。

主要发现

  • 缬沙坦组(n=168)NT-proBNP AUC中位数1.19(IQR 0.91-1.64),沙库巴曲/缬沙坦组(n=167)为1.08(IQR 0.75-1.60)。
  • 沙库巴曲/缬沙坦未改善存活且院外无心衰事件的临床复合终点。

临床怎么用

  • 对于晚期HFrEF且近期NYHA IV级症状患者,沙库巴曲/缬沙坦在降低NT-proBNP方面未优于缬沙坦,需权衡高钾血症风险。

局限性

  • 试验因COVID-19风险提前终止。
  • 49例(29%)患者在24周试验期间停用沙库巴曲/缬沙坦。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The use of sacubitril/valsartan is not endorsed by practice guidelines for use in patients with New York Heart Association class IV heart failure with a reduced ejection fraction because of limited clinical experience in this population. OBJECTIVE: To compare treatment with sacubitril/valsartan treatment with valsartan in patients with advanced heart failure and a reduced ejection fraction and recent New York Heart Association class IV symptoms. DESIGN, SETTING, AND PARTICIPANTS: A double-blind randomized clinical trial was conducted; a total of 335 patients with advanced heart failure were included. The trial began on March 2, 2017, and was stopped early on March 23, 2020, owing to COVID-19 risk. INTERVENTION: Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or valsartan (target dose, 160 mg twice daily) in addition to recommended therapy. MAIN OUTCOMES AND MEASURES: The area under the curve (AUC) for the ratio of N-terminal pro-brain natriuretic peptide (NT-proBNP) compared with baseline measured through 24 weeks of therapy. RESULTS: Of the 335 patients included in the analysis, 245 were men (73%); mean (SD) age was 59.4 (13.5) years. Seventy-two eligible patients (18%) were not able to tolerate sacubitril/valsartan, 100 mg/d, during the short run-in period, and 49 patients (29%) discontinued sacubitril/valsartan during the 24 weeks of the trial. The median NT-proBNP AUC for the valsartan treatment arm (n = 168) was 1.19 (IQR, 0.91-1.64), whereas the AUC for the sacubitril/valsartan treatment arm (n = 167) was 1.08 (IQR, 0.75-1.60). The estimated ratio of change in the NT-proBNP AUC was 0.95 (95% CI 0.84-1.08; P = .45). Compared with valsartan, treatment with sacubitril/valsartan did not improve the clinical composite of number of days alive, out of hospital, and free from heart failure events. Aside from a statistically significant increase in non-life-threatening hyperkalemia in the sacubitril/valsartan arm (28 [17%] vs 15 [9%]; P = .04), there were no observed safety concerns. CONCLUSIONS AND RELEVANCE: The findings of this trial showed that, in patients with chronic advanced heart failure with a reduced ejection fraction, there was no statistically significant difference between sacubitril/valsartan and valsartan with respect to reducing NT-proBNP levels. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02816736.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Mann, Givertz, Vader, et al. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 34730769. doi:10.1001/jamacardio.2021.4567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。